Article

Second-quarter merger predicted for AMO, VISX

Santa Ana, CA—The merger of Advanced Medical Optics Inc. (AMO) and VISX Inc. is taking a little longer to complete than anticipated, as auditors work to finish the companies' year-end financial statements.

Santa Ana, CA-The merger of Advanced Medical Optics Inc. (AMO) and VISX Inc. is taking a little longer to complete than anticipated, as auditors work to finish the companies' year-end financial statements.

The companies expect to finalize the merger during the second quarter of this year, despite earlier predictions that it would happen during the first quarter. The companies attributed the delay to securities laws that now require financial statements to be included in their joint proxy statement/prospectus, which is mailed to stockholders prior to their respective stockholder meetings.

Meanwhile, AMO is taking a page from the VISX book and bolstering its customer service by hiring in-house field service engineers.

At the time of the merger, AMO said it would like to incorporate VISX's emphasis on customer service.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.